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THE treatment of chronic lymphatic leukaemia has been assessed during the
past ten years. External radiation therapy, radioisotopes such as 321p and chemo-
therapy have proved to be effective in the management ofthis disease (Dameshek
and Gunz, 1964; Karnofsky, 1966; La Due and Molander, 1964; Wintrobe,
1961). With the adequate administration of radiotherapy, chlorambucil and
prednisone, patients with chronic lymphatic leukaemia can be maintained in
fairly good clinical conditions for long periods of time, although whether the
results of treatment can affect survivals is still debatable.
There have been no new drugs or new methods of treatment for chronic
lymphaticleukaemia inthepast fewyears (Dameshek andGunz, 1964; Karnofsky,
1966; La Due and Molander, 1964; Wintrobe, 1961). In our Institutes we have
conducted experiments since 1961 into the therapeutic effects of a radioactive
contrast medium (Lipiodol F 1311) introduced into the lymphatics of the dorsum
of the foot in more than 200 cases of retroperitoneal malignant lymphomas
(Buraggi, D'Amico and Fava, 1963; Chiappa, 1963; Chiappa, Galli and Palmia,
1964; Chiappa et al., 1965; Chiappa, Galli and Severini, 1964) as well as in
several patients with carcinomas metastatic to the retroperitoneal nodes (Chiappa
et al., 1966; Chiappa et al., 1963).
Such a wide experience has proved that the administration ofLipiodol F 131I
provides agoodpalliative treatmentwith aremarkable andlong-standing shrinkage
of all adequately opaque nodes without producing untoward effects (Bagliani,
Chiappa and Galli, 1964). This treatment has been called by us endolymphatic
radiotherapy.
The present report is a preliminary one and deals with a group of 17 patients
with chronic lymphatic leukaemia in which Lipiodol F 1311 has been injected into
the lymph channels ofthe dorsum ofthe foot in order to see whether a good control
of the retroperitoneal adenopathies could be achieved also in this disease.
MATERIALS AND METHODS
Seventeen patients with chronic lymphatic leukaemia have been studied.
The morphological diagnosis was made through bone marrow aspirates and peri-
pheral blood smears. The patients were classified into 4 groups according to
the four types proposed by Dameshek and Gunz (1964).
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Type I.-Fairly benign process with mild leukocytosis and adenopathy which
persists for many years without doing the patient any harm.
Type II.-Marked adenopathy, hepatomegaly and splenomegaly, high leuko-
cytosis andlymphocytosis withextensiveleukaemicinfiltrationofthe bonemarrow.
Type III.-This variety runs a mild course and is associated with an auto-
immune haemolytic anaemia.
Type IV.-Includes forms where the most significant clinical findings are due
to chronic dermatologic disturbances.
Lipiodol F 131J was injected into the lymphatics of the dorsum of the foot
following the technique proposed by Kinmonth (Kinmonth, Taylor and Herper,
1955). The doses per foot ranged from 0*7 to 2-5 mc/c.c., as can be seen from
Table I. Three patients (Cases No. 4, 11, 15) received two injections ofLipiodol F
131I, one because ofrelapse (Case 4) and two because theretroperitoneal nodes were
too large to be filled adequately with the standard dose of 10 c.c. of radioactive
contrast medium in each lower limb. Two patients (Cases No. 7, 8) were injected
only in one lower limb because a good lymph vessel was not found in the opposite
side. One patient (Case No. 9) received normal Lipiodol F in one foot and
Lipiodol F 131J in the opposite one.
RESULTS
The most important findings are summarized in Table I. Three cases (No. 7,
13, 17) have been classified as Type I patients. All the otherfourteencasesbelong
TABLE I
Lymph Node Involvement Lipiodol
Clinical Variety
F131
Case , Haemolytic Ingui- Para- Doses
No. Patient Age Sex I II III IV Anaemia nal Iliac aortic (mc/c.c.) Chemotherapy
1 . R.M.. 64 M. + R,L R,L R,L 0-8 . TEM, prednisone
2. I.G. .63 M. + R,L R,L R,L 0 8
3. T.C. .61 M. + . R,L R,L R,L . 0 8
4 . R.E. . 62 M. + . r * R,L L .0 7 TEM,prednisone 4 . R.E. 62 M. + { * L LL 2 TEMpchlorambucil
5. R.F. .64 M. + R,L R,L R,L 2 - 5
6. G.F. . 62 F. + R,L R,L R,L 2-5 . TEM, prednisone
chlorambucil
7 .G.L. .70 M. + . L . 2 . -
8 M.R.. 65 F. + °R,L R,L R,L . 2 -5 TEM, chlorambucil
9 C.S. . 56 M. + . R,L R,L R,L 2- 5 TEM, chlorambucil
10 B.R. . 72 F. + R,L R,L R,L . 2 5 . TEM, chlorambucil
11. M.G. .52 M. + **R,L R,L R,L 2-5 . TEM
\ R,L R,L R,L 2- 5 . chlorambucil
12 B.S. . 67 M. + + . R,L R,L R,L 2- 5 . TEM
13. D.T. .67 F. + . L . 25. -
14 . SG. . 61 M. + R,L R,L R,L . 2 - 5
15 . S.G. . 44 M. + f***R,L R,L R,L . 2-5 . chlorambucil
R,L R,L R,L . 2-5
16 G.G. . 51 M. + . . L L 2-5 chlorambucil
17 . F.D. . 52 M. ± . R . 2-5 -
R R: right.
L left.
*: the second dose was injected 3 years after the first.
** the second dose was injected 15 days after the first.
: the second dose was injected 7 days after the first.
0: Lipiodol F 131J injected only in the right foot.S. CHIAPPA et al.
to Type II and only one patient (Case No. 12) was proved to have an haemolytic
anaemia (positive Coomb's test). Extensive retroperitoneal node involvement
was found in practically all patients with the classic form of chronic lymphatic
leukaemia. A good lymph node shrinkage was observed in all treated patients
(Fig. 1, 2, 3, 4, 5) even in cases 2, 3 and 4 who received low doses ofLipiodol F 1311
(0.7-0-8 mc/c.c.). The initial node regression was already present before the
end ofthe second week (Fig. 2, 5). The lymph node shrinkage was observed with
monthly follow-up films until Lipiodol F 131J was completely reabsorbed (about
6-10 months). In one case (Fig. 1) the contrast medium remained in the lymph
nodes two years. This allowed us to detect a relapse in the external iliac chains.
In one patient (Case No. 4) because of inadequate filling of the left para-aortic
and inguinal nodal masses, external radiation therapy with Cobalt was used.
Two patients (Cases 2 and 3) died, outside the hospital, 1 month after the adminis-
tration of endolymphatic radiotherapy. The exact clinical cause of death is
unknown. In all other patients no complications or untoward effects due to
Lipiodol F 131I were observed (pulmonary or hepatic insufficiency) nor were
haemolytic anaemias detected.
DISCUSSION
It is well-known that chronic lymphatic leukaemia is a neoplastic disease
which belongs to the group oflymphoproliferative disorders (Dameshek and Gunz,
1964). Its causeremains stillunknown, andthedisease, whichis self-perpetuating,
EXPLANATION OF PLATES
FIG. 1.-Case No. 6, G.F.
(A) All retroperitoneal node chains appear to be extensively involved.
(B) Follow-up film taken 9 months after endolymphatic radiotherapy shows a goodshrinkage
of all involved nodes.
(C) Follow-up film taken 2 years later allows to detect a relapse in both external iliac chains
(arrows).
FIG. 2.-Case No. 15, S.G.
(A) Pathologic lymph nodes are present in both common iliac chains. Only a small amount
of Lipiodol F 131I opacifies some of the para-aortic nodes.
(B) Seven days later a second injection of Lipiodol F l3lI has been performed, An initial
shrinkage of the iliac nodes is already present. The para-aortic nodes appear now better
opacified.
(C) Follow-up film taken 45 days after the second injection of Lipiodol F 13'I shows a good
shrinkage of all opacified nodes.
FIG. 3.-Case No. 12, B.S.
(A) All the retroperitoneal lymph node chains appear pathologically involved.
(B) Follow-up film taken 21 days after endolymphatic radiotherapy shows a marked shrinkage
of all opacified nodes.
FIG. 4.-Case No. 8, M.R.
(A) In this case the radioactive contrast medium was injected only in the right lower limb
(no good lymph channels have been found in the left side). All the right lymph node chains
appear to be involved and irregularly filled.
(B) Follow-up film taken 9 months after endolymphatic radiotherapy shows a very good
shrinkage ofallpathologic nodes.
FIG. 5.-Case No. 11, M.G.
(A) Enormous lymph nodes are present in all retroperitoneal chains. A partial filling ofthe
pathologic nodal masses has been obtained in the para-aortic region because almost all the
contrast medium has been retained in the voluminous inguinal and iliac nodes.
(B) Follow-up film taken 40 days after the second dose of Lipiodol F 13'I shows a further
shrinkage ofall retroperitoneal nodes.
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with or without therapy is invariably fatal. All the therapeutic efforts, with
specific and supportive therapies, are designed to control the disease for variable
lengths of time, especially when large adenopathies, extensive marrow invasion,
hepatosplenomegaly and haemolytic anaemia are present. Responsive patients
are maintained in relatively good health during the major portion ofthe course of
the disease.
The treatment of choice will depend on the patient's clinical condition and the
physician's facilities and experience. Treatment is not indicated for the benign
form (Type I) unless symptoms arise or the leukocyte count reaches very high
levels. On the contrary therapy is necessary in the typical "aggressive " variety
(Type II) which in the majority of cases is a symptom-producing disease. In
these cases external radiation therapy is given to bulky nodes wherever the loca-
tion, or to the enlarged spleen. Alkylating agents (TEM, chlorambucil, cyclo-
phosphamide) are often given in combination (Dameshek and Gunz, 1964;
Karnofsky, 1966; La Due and Molander, 1964; Wintrobe, 1961), and usually
administered in a cautious schedule to avoid excessive destruction of lymphoid
tissue or severe bone marrow depression which can result in serious complications
more disabling than the disease itself (Diamond and Miller, 1961).
As can be seen from our limited case material, retroperitoneal node involvement
is very frequent in Type II of chronic lymphatic leukaemia (14/17 cases). All
3 Type I patients had mild retroperitoneal adenopathy. The large nodal masses
which are often symptomatic (constipation, diarrhoea, back pain) require therapy
and specifically radiation therapy to produce a fairly rapid and adequate shrinkage
of the bulky nodes. Our experience achieved with the treatment of similar
clinical situations in malignant lymphomas suggested the choice of Lipiodol F 1311
over cobalt-teletherapy for the inguinal and the retroperitoneal node involvement
(Chiappa, Galli and Severini, 1964). The reasons for this preference are due to
the fact that endolymphatic radiotherapy can be administered in one single injec-
tion and does not produce any radiation sickness effects which often occur when
multiple large ports are employed over the abdomen. Endolymphatic radio-
therapy has been administered in combination with polyfunctional alkylating
agents (TEM, chlorambucil) and corticosteroids (prednisone) to control all sites of
the disease. The promising clinical results obtained by these therapeutic asso-
ciations (Table I) warrant further trials with larger numbers of patients, especially
in order to determine the length ofregression.
A few other authors in Europe (Jantet, 1962; Picard et al., 1964) and in the
U.S.A. (Ariel, 1963; Liebner, 1965; Seitzman et al., 1963; Seitzman et al., 1964)
have recently used endolymphatic radiotherapy for the palliative treatment of
retroperitoneal metastases of malignant lymphomas and carcinomas. We are
not aware of any therapeutic trial undertaken in chronic lymphatic leukaemia.
In conclusion we recommend endolymphatic radiotherapy in the treatment of
inguinal and retroperitoneal node involvement in Type II of chronic lymphatic
leukaemia. This method of treatment seems to be effective without doing any
harm to the patients which are not exposed to the side effects ofradiation therapy
when high voltage machines and large ports are used. We do not advise endo-
lymphatic radiotherapy in Type I patients to avoid excessive destruction ofprob-
ably normal lymphoid tissue and the possible triggering of a haemolytic anaemia
(Dameshek and Gunz, 1964) although in our 3 cases such a complication has not
been observed after 6-10 months from the treatment.
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Endolymphatic radiotherapy does not seem to affect bone marrow directly.
Not one of our cases treated with Lipiodol F 1311 (Table I) showed anaemia,
leukopenia or thrombocytopenia. A definitive conclusion however cannot be
drawn from our case material because most of the patients received a combined
treatment with alkylating agents.
SUMMARY
Seventeen patients with chronic lymphatic leukaemia were injected with
Lipiodol F 131I (endolymphatic radiotherapy) to control the inguinal and the retro-
peritoneal adenopathy. In all Type II patients a good long-standing shrinkage of
all adequately opacified nodes was observed. No untoward effects, secondary to
the administration ofLipiodol F 1311, were seen. Endolymphatic radiotherapy is
recommended instead of conventional radiation therapy administered with high
voltage machines as the palliative treatment ofchoice in combination with alkyla-
ting agents to control the inguinal and retroperitoneal adenopathies in the classic
aggressive (Type II) variety of chronic lymphatic leukaemia. Endolymphatic
radiotherapy is not advised routinely in the relatively asymptomatic (Type I)
form of the disease.
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